20-F: Anbio Biotechnology Reports Fiscal Year 2024 Results, Highlights Growth and Strategic Initiatives

Anbio Biotechnology's 20-F filing reveals a year of revenue growth, strategic market expansion, and ongoing efforts to navigate regulatory landscapes and diversify its IVD product portfolio.

Summary

• Anbio Biotechnology reported a revenue increase of 21.9% in 2024, reaching $8.19 million, compared to $6.71 million in 2023.
• The company's gross profit for 2024 was $5.89 million, with a gross margin of 71.9%, a significant increase from 50.1% in 2023.
• Respiratory diseases and COVID-19 related products accounted for 54% of the company's revenue in 2024, a decrease from 60% in 2023 and 99% in 2022, indicating diversification efforts.
• Operating expenses increased to $3.89 million in 2024, primarily due to higher professional fees related to the company's public listing.
• Research and development expenses increased to $454,227 in 2024, reflecting ongoing efforts in medical device and assay development.
• The company completed its initial public offering (IPO) on February 20, 2025, raising $8 million through the sale of 1,600,000 Class A Ordinary Shares at $5.00 per share.
• Anbio is focusing on expanding its global IVD market share, targeting key regions including the EU, APAC, North America, South America, and Africa.
• The company is preparing for IVDR registration of its IVD products in the EU, with anticipated approval dates ranging from 2027 to 2029 depending on the device class.
• Anbio's strategy includes diversifying its IVD product portfolio, expanding market share, and focusing on efficient manufacturing and cost management.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with revenue growth and improved profitability, but also highlights risks and challenges associated with regulatory compliance, market competition, and reliance on third parties.

Positives

• Revenue increased by 21.9% in 2024, indicating growth.
• Gross margin improved significantly to 71.9%, demonstrating increased profitability.
• Diversification efforts are reducing reliance on COVID-19 related products.
• Successful IPO provides additional capital for expansion and operations.
• The company is actively expanding its market presence in key regions globally.
• The company is developing and selling high-quality, easy to use diagnostic products based on established and widely used IVD technology platforms and their scientific principles with competitive prices to increase our overall share in the diagnostic market.

Negatives

• Operating expenses increased due to public listing costs.
• The company relies on a limited number of customers for a substantial portion of its revenue.
• The company relies on a limited number of suppliers for a substantial portion of its cost of sales.
• The company may face delays or failures during the registration process as we recertify all of our supplied IVD products under the IVDR 2017/746, which could a have an adverse effect on our future growth and business in the EU.

Risks

• Reliance on third-party suppliers and distributors poses a risk to business operations.
• Geopolitical risks may adversely impact economic conditions, increase market volatility, cause operational disruption to us and impact our strategic plans, which could have adverse effects on our business and its profitability.
• Failure to obtain and maintain adequate coverage and reimbursement from third-party payors for our IVD products in the US, the US market opportunity for our tests may be less than expected.
• The company may be unable to timely and accurately respond to changes in the latest market trends for our IVD products due to future development of COVID-19 pandemic.
• The company may face intellectual property infringement claims, which could be time-consuming and costly to defend and may result in the loss of significant rights by us.
• The company may incur losses or experience disruption of our operations as a result of unforeseen or catastrophic events, including pandemics, terrorist attacks, or natural disasters.
• Potential conflicts of interest may arise between the dual roles of our CEO and he may not act in our best interests.
• Our corporate actions will be substantially controlled by our Class B shareholders, CVC Investment and Northwestern Investment, which will have the ability to control or exert significant influence over important corporate matters that require approval of shareholders, which may deprive you of an opportunity to receive a premium for your Class A Ordinary Shares and materially reduce the value of your investment.
• The trading price of our Class A Ordinary Shares may be volatile, including any stock run-ups, which could result in substantial losses to you.
• There is uncertainty as to the enforceability in the Cayman Islands of judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States.

Future Outlook

Anbio aims to expand its global IVD market share, targeting key regions and navigating complex regulatory landscapes through direct sales, partnerships, and product registrations. The company also plans to establish a diversified global customer portfolio and continue promoting its line of diagnostic products with global and regional market conditions in mind.

Industry Context

Anbio operates in the in vitro diagnostics (IVD) industry, which is characterized by rapid technological developments and increasing demand for point-of-care testing solutions. The company's focus on speed, innovation, and low-cost solutions aligns with the industry's shift towards precision medicine, population health, and chronic disease management.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• The document does not list specific comparible companies, projects, and results.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of this annual report, we are not aware that we are involved in any legal or administrative litigation that may have a material adverse effect on the companys business, balance sheet, operating performance and cash flow.

Related Party Transactions

• Our former CFO, Richard Chen, is one of the partners of CLC LLP (hereafter CLC).
• CLC provided accounting services to our company from late 2021.
• 2021 and 2022 accounting fee incurred was $97,592.34.
• For yearend December 31, 2023, the total accounting fee incurred to CLC is $54,746.
• We did not incur any accounting fees with CLC LLP in 2024.

Stakeholder Impact

• Shareholders: The IPO provides new investment opportunities, but the dual-class structure concentrates voting control.
• Employees: The company's growth and strategic initiatives may create new job opportunities.
• Customers: The company's focus on innovation and low-cost solutions aims to improve access to diagnostic testing.
• Suppliers: The company's reliance on a limited number of suppliers creates a dependency risk.
• Creditors: The company's financial performance and IPO proceeds may improve its creditworthiness.

Next Steps

• Continue to promote our line of diagnostic products with global and regional market conditions in mind
• Diversify Portfolio of IVD Products via Sales and Marketing
• Provide Superior Quality Products and Customer Service
• Focus on Efficient Manufacturing and Cost Management

Key Dates

Keywords

IVD, diagnostics, revenue, COVID-19, IPO, market expansion, regulatory approval, Class A Ordinary Shares, Class B Ordinary Shares, Anbio Biotechnology